Indian drug 2DG can reduce heart damage by coronavirus, find US researchers
Their findings, based on research with fruit flies and mouse heart cells, were published in 'Communications Biology,' a 'Nature' journal
A team of US researchers has identified how a specific protein in coronavirus damages heart tissue and they used a drug, currently in emergency use for the treatment of COVID in India, to reverse the toxic effects of that protein on the heart.
Dr Reddy’s Laboratories last year announced the commercial launch of 2-deoxy-D-glucose (2DG) for treatment of COVID-19. 2DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
Now, researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Precision Disease have used 2DG to reverse the toxic effects of that protein on the heart.
The researchers said that fortunately, 2DG is inexpensive and is used regularly in laboratory research and is being used in clinical trials in India. The drug has not yet been approved by the US Food and Drug Administration (FDA) to treat the disease.
“Our research shows that individual SARS-CoV-2 proteins can each do major damage to specific tissues in the body – similar to what has been found for other viruses like HIV and Zika,” said senior author Zhe Han, Professor, Medicine, and Director, Center for Precision Disease Modelling, UMSOM.
“By identifying these processes of injury in each tissue, we can test drugs to see whether any can reverse this damage; those drugs that show promise can then be